ASX:LDX

Lumos Diagnostics (LDX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free LDX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Lumos Diagnostics alerts:

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Lumos Diagnostics

Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

Ad Manward Press

Can't believe it's happening again

We explain how this event works in full right here.

LDX Stock News Headlines

April 11, 2024 | proactiveinvestors.com

Lumos Diagnostics’ breakthroughs in paediatric care with FebriDx

January 30, 2024 | msn.com

ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 11, 2023 | investing.com

Lumos Diagnostics Holdings Ltd (LDX)

September 10, 2023 | finance.yahoo.com

Lumos Diagnostics Holdings Limited (LDX.AX)

September 1, 2023 | finance.yahoo.com

Lumos Diagnostics Holdings Full Year 2023 Earnings: US$0.038 loss per share (vs US$0.30 loss in FY 2022)

August 23, 2023 | wsj.com

Lumos Diagnostics Holdings Ltd.

August 18, 2023 | finance.yahoo.com

Lumos Receives US FDA Clearance for FebriDx®

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 15, 2022 | finance.yahoo.com

Liverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service at More Than 100 Community Pharmacies

See More Headlines

Receive LDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: ASX:LDX
CUSIP: N/A
CIK: N/A
Web: lumosdiagnostics.com
Phone: 61 3 9692 7222
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,820,000.00
Net Margins: -107.38%
Pretax Margin: N/A
Return on Equity: -87.62%
Return on Assets: -26.13%

Debt

Debt-to-Equity Ratio: 92.41
Current Ratio: 0.69
Quick Ratio: 0.77

Sales & Book Value

Annual Sales: $8.21 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: A$0.02 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 481,300,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.74

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Samuel Lanyon
Executive Chairman
Mr. Douglas Ward
CEO, MD & Director
Mr. Barrie Lambert
Chief Financial Officer
Dr. Sacha Dopheide Ph.D.
Chief Technology Officer
Ms. Jennifer Christiansen
Vice President of Corporate Marketing & Communications
Ms. Sarah Glubka
Senior Director of Human Resources
Mr. Paul Kase
Senior Vice President of Commercial Operations
Ms. Tracy Weimar BA
MBA, Company Secretary

Key Competitors

View All Competitors

Insiders

This page (ASX:LDX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lumos Diagnostics (LDX) Stock Price, News & Analysis

About Lumos Diagnostics

LDX Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info